8-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

Pursuantto Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): July 15, 2021

USAEQUITIES CORP.

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

Registrant’s telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securitiesregistered pursuant to Section 12(b) of the Act:

Item 7.01 Regulation FD Disclosure.

On July 15, 2021, USA Equities Corp (the “Company”) issued a press release announcing certain unaudited financial results for the quarter ended June 30, 2021 and providing certain guidance as to future revenues. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

ITEM9.01 Financial Statements and Exhibits

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT99.1

USAEquities Corp. Announces Strong Second Quarter 2021 Financial Results

West Palm Beach, FL – July 15, 2021 – USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announced preliminary second quarter financial results for the period ended June 30, 2021, reporting strong sequential growth on several fronts.

In the second quarter of 2021, revenue increased 49.9% sequentially to approximately $456,219 compared to first quarter 2021. Gross profit increased 55.5% sequentially to $207,717 or a 45.5% gross margin in second quarter 2021 compared to $133,579 of gross profit or a 43.9% gross margin in first quarter 2021. In addition, the Company ended the second quarter with $145,947 in cash and cash equivalents, a 54.7% increase above the year-end balance at December 31, 2020.

“We had a very strong second quarter and delivered on our prior guidance for both revenue growth and gross margin expansion sequentially compared to the first quarter of 2021. Our growth reflected increased sales of allergy diagnostic kits and immunotherapy treatments, expansion of our customer base and strong execution by our team as we leveraged our deep applications expertise and industry relationships. Our targeted solutions and compelling customer value proposition are clearly resonating with independent medical practitioners. We remain disciplined allocators of capital with the increase in our second quarter cash balance allowing us to further opportunistically invest in driving our growth strategy and anticipate continued revenue growth in the third quarter,” said Troy Grogan, CEO of USA Equities Corp.

“We also continue to focus on prudently adding scale to our medical device technology and software platform and customer footprint. The acquisition of AllergiEnd^®^ assets in June is a terrific strategic fit that further enhances our recurring revenue business model. In addition, we recently announced a distribution agreement with a prominent physician management services firm and a co-promotion agreement with an ENP Network for AllergiEnd® products and services. These new relationships enable us to further penetrate the large and growing addressable market of independent medical practitioners and over time potentially launch additional products through these distribution channels” concluded Grogan.

AboutUSA Equities Corp.

USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians and other medical practitioners to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease population.

For additional information, visit the Company’s website at www.USAQCorp.com

Forward-LookingStatements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.